Sarclisa (Isatuximab-irfc)
- Medicine Name: Sarclisa
- Generic Name: Isatuximab-irfc
- Dosage Form & Strength: Injections: 100 mg/5 mL (20 mg/mL) and 500 mg/25 mL (20 mg/mL)
- Manufactured By: Sanofi
Sarclisa is a CD38-directed cytolytic antibody used, along with medicines pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have previously received at least a couple of therapies including a drug lenalidomide and a proteasome inhibitor.
Recommended Dosage: The recommended dose is 10 mg/kg as an intravenous infusion every week for 4 weeks followed by every 2 weeks along with pomalidomide and dexamethasone until the disease is progressive or in case of unacceptable toxicity. Each treatment cycle typically consists of a 28-day period. If a planned dose of sarclisa injection is missed, administer the dose as promptly as possible and adjust the treatment schedule accordingly, maintaining the treatment interval.
- Use of injection isatuximab-irfc 100 mg / 500 mg is restricted in patients with severe hypersensitivity to isatuximab-irfc or to any of its existing excipients.
- Infusion-related reactions have been observed in patients treated with isatuximab-irfc. To reduce the risk and severity of infusion-related reactions, premedicate patients before isatuximab-irfc infusion with acetaminophen, diphenhydramine, H2 antagonists, or equivalent; dexamethasone.
- The sarclisa 100 mg injection may cause neutropenia. Monitor CBC counts periodically during treatment. Consider the use of antibiotics and antiviral prophylaxis while on treatment. Asess patients with neutropenia for signs/symptoms of infection.
- Monitor vital signs/symptoms frequently while on the entire isatuximab infusion. For patients with grade 1/2 reactions, interrupt isatuximab infusion and provide apt medical assistance.
- On behalf of the mechanism of action, sarclisa 500 mg or 100 mg can cause fetal harm if administered to a pregnant woman. This medicine may cause fetal immune cell depletion and reduction in bone density.
- In some cases, second primary malignancies were reported. Patients should be monitored for the development of second primary malignancies, as per IMWG guidelines.
What documents are required to import SARCLISA to India?
SARCLISA (isatuximab-irfc) injection can be imported by patients or government hospitals on the name of the patients only.
The following documentation required to import the product:
- Valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients id proof (issued by government of India)
How does order be confirmed?
The order will be confirmed only after the receipt of:
- Valid prescription of Doctor
- Import permit if applicable
Is SARCLISA available in India?
SARCLISA (isatuximab-irfc injection) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
- On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
SARCLISA can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of SARCLISA (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for sarclisa price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements
Indian Pharma Network is able to source the SARCLISA (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Sarclisa®?
Isatuximab-irfc is Generic Name for the trade name drug Sarclisa®.
What is the Manufacturer Name of Sarclisa®?
Sarclisa® is manufactured by Sanofi.
Is Sarclisa® approved by the FDA?
Yes, Sarclisa® is approved by the FDA. Date of approval: March 31, 2021.
What is Sarclisa®?
Sarclisa® (isatuximab injection) is specifically the newest anti-CD38 monoclonal antibody medication approved for use in multiple myeloma (MM).
What is the dosage and form of Sarclisa® supplied?
Sarclisa® is supplied as Injections: 100 mg/5 mL (20 mg/mL) and 500 mg/25 mL (20 mg/mL) for intravenous administration.
What are the most common side effects due to Sarclisa®?
Most common side effects due to Sarclisa® include: upper respiratory tract infection, neutropenia, infusion-related reactions, pneumonia, and diarrhea.
How much does Sarclisa cost in India?
The sarclisa cost in India is very reasonable. In order to procure this multiple myeloma medicine authentically, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Sarclisa®?
Store the vials of Sarclisa in a refrigerator at 36°F to 46°F (2°C to 8°C) in the original carton in order to protect from light. Neither freeze nor shake.
What are the Highlights of prescribing information for Sarclisa®?
Click Here to download full Sarclisa prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.